Neuromuscular Blockade and Surgical Conditions
Information source: Sheba Medical Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Morbid Obesity
Intervention: Profound neuromuscular blockade (Rocuronium, Rocuronium bromide, sugammadex, Bridion) (Drug)
Phase: N/A
Status: Not yet recruiting
Sponsored by: Sheba Medical Center Official(s) and/or principal investigator(s): Haim Berkenstadt, MD, Principal Investigator, Affiliation: Sheba Medical Center
Overall contact: Haim Berkenstadt, MD, Phone: 97235302966, Email: haim.berkenstadt@sheba.health.gov.il
Summary
The aim of the present study is to prospectively assess whether deep neuromuscular blockade
(NMB) (zero response to train of four and a post tetanic count of no more than 10 responses
using a nerve stimulator monitoring) until the end of surgery, followed by sugammadex
(bridion®) reversal is superior to the present practice of gradual NMB reduction at the end
of surgery followed by neostigmine (Prostigmin®, Vagostigmin®) reversal, in patients
undergoing laparoscopic sleeve gastrectomy. The investigators hypothesize that providing
deep NMB throughout the procedure creates better conditions for surgery, while reversal of
deep NMBwith sugammadex (bridion®) will enable quick and full reversal of relaxation and
fewer postoperative respiratory events as compared to neostigmine (Prostigmin®,
Vagostigmin®)reversal. Participants will be followed for the duration of hospital stay, an
expected average of 7 days.
Clinical Details
Official title: The Influence of the Magnitude of Neuromuscular Blockade on the Surgical Conditions During Laparoscopic Sleeve Gastrectomy
Study design: Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Primary outcome: Subjective surgeon feedback on the exposure and surgical field.
Secondary outcome: Incidence of respiratory adverse events
Detailed description:
In laparoscopic bariatric procedures, CO2 is used to insufflate the peritoneal cavity and
increase the intra-abdominal pressure for optimal exposure and a suitable operating field.
However, the increased intra-abdominal pressure during pneumoperitoneum has profound
physiological effects including a reduction in urine output,portal venous flow,respiratory
compliance,and cardiac output.
Abdominal muscle relaxation and changes in abdominal wall compliance, produced by the use of
anesthetics and muscle relaxants, are important contributors for the achievement of optimal
surgical field using minimal abdominal pressure. A practical dilemma is how to maintain good
surgical conditions till the end of the operative procedure by deep anesthesia and muscle
relaxation on one hand, and to have an awake and spontaneously breathing patient at the end
of surgery on the other.
Reversal agents are often used to ensure the reversal of nondepolarizing neuromuscular
blockade (NMB). The most widely used is the acetylcholinesterase inhibitor neostigmine
(Prostigmin®, Vagostigmin®). However, neostigmine is only partially effective when NMB is
deep (less then 1 response using train of four monitoring) and may also be associated with
adverse effects, such as cholinergic cardiovascular and gastrointestinal events. Sugammadex
(bridion®) is a modified gamma cyclodextrin specifically designed for the reversal of NMB
induced by the aminosteroid muscle relaxants including rocuronium bromide (Zemuron®,
Esmeron®). Sugammadex (bridion®) acts by encapsulating unbound rocuronium bromide (Zemuron®,
Esmeron®)molecules and reducing their concentration at the neuromuscular junction. Studies in
surgical patients have shown that sugammadex (bridion®) rapidly and safely reverses
rocuronium bromide (Zemuron®, Esmeron®)induced NMB. Unlike acetylcholinesterase inhibitors,
sugammadex (bridion®) is also effective in the reversal of deep NMB (no response in train of
four monitoring or even no response in post tetanic count monitoring).
Laparoscopic weight reduction surgery requires the appropriate use of muscle relaxation;
however, uncertainty remains including indeterminate dosing and unpredictable effect.
Additionally, the time to the recovery to a train of four (TOF) ratio of 0. 9 in the obese
[25. 9 (6. 7, 13. 5-41. 0) min] and the overweight groups [14. 6 (7. 7, 3. 3-28. 5) min] were
significantly longer than that in the normal weight group [6. 9 (2. 0, 3. 0-10. 7) min].
Therefore, obese patients are at increased risk for residual muscle relaxation following
surgery. Sugammadex (bridion®) has recently been found to reach a peak effect faster than
neostigmine(Prostigmin®, Vagostigmin®), in obese patients. In this study, the time to a TOFR
≥ 0. 9 was 13 min with 50 μg/kg neostigmine (Prostigmin®, Vagostigmin®)and only 1. 7 min with
2 mg/kg sugammadex. Therefore, it appears that sugammadex (bridion®) may more predictably
prevent the occurrence of residual muscle relaxation compared to neostigmine (Prostigmin®,
Vagostigmin®).
The aim of the present study is to prospectively assess whether deep NMB (zero response to
train of four and a post tetanic count of no more than 10 responses using a nerve stimulator
monitoring) till the end of surgery, followed by sugammadex (bridion®) reversal is superior
to the present practice of gradual NMB reduction at the end of surgery followed by
neostigmine (Prostigmin®, Vagostigmin®)reversal, in patients undergoing laparoscopic sleeve
gastrectomy. The investigators hypothesize that providing deep NMB throughout the procedure
creates better conditions for surgery, while reversal of deep muscle relaxation with
sugammadex (bridion®) will enable quick and full reversal of relaxation and fewer
postoperative respiratory events as compared to neostigmine (Prostigmin®, Vagostigmin®)
reversal. Surgical conditions will be assessed by the surgeons, blinded to the treatment
given to the patients, on a 1-4 Likert scale in 5 minutes intervals from abdominal
insufflation with gas till the end of surgery (estimated time of 120 minutes). Participants
will be followed for respiratory adverse events from admission to the post anesthesia care
unit to discharge to the surgical department (continuous measurement of hemoglobin oxygen
saturation and respiratory rate for an expected average of 3 hours) and from admission to
the surgical department till the time of home discharge (measurement of hemoglobin oxygen
saturation and respiratory rate every 6 hours for an expected average of 5 days).
Eligibility
Minimum age: 20 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- American Society of Anesthesiologists physical status Class I-III, scheduled to
undergo elective sleeve gastrectomy
Exclusion Criteria:
- Neuromuscular disorder affecting NMB
- history of malignant hyperthermia
- significant renal dysfunction
- allergy to medications used during general anesthesia
- concurrent use of medications known to interfere with NMBAs or with sugammadex
(antibiotics, anticonvulsants, magnesium salts).
Locations and Contacts
Haim Berkenstadt, MD, Phone: 97235302966, Email: haim.berkenstadt@sheba.health.gov.il
Sheba Medical Center, Tel Hashomer, Israel; Not yet recruiting Haim Berkenstadt, MD, Phone: 97235302966, Ext: 2966, Email: haim.berkenstadt@sheba.health.gov.il Haim Berkenstadt, MD, Principal Investigator
Additional Information
Related publications: Daskalakis M, Scheffel O, Weiner RA. High flow insufflation for the maintenance of the pneumoperitoneum during bariatric surgery. Obes Facts. 2009;2 Suppl 1:37-40. doi: 10.1159/000198252. Epub 2009 Mar 18. Review. Matot I, Paskaleva R, Eid L, Cohen K, Khalaileh A, Elazary R, Keidar A. Effect of the volume of fluids administered on intraoperative oliguria in laparoscopic bariatric surgery: a randomized controlled trial. Arch Surg. 2012 Mar;147(3):228-34. doi: 10.1001/archsurg.2011.308. Epub 2011 Nov 21. Nsadi B, Gilson N, Pire E, Cheramy JP, Pincemail J, Scagnol I, Meurisse M, Defraigne JO, Detry O. Consequences of pneumoperitoneum on liver ischemia during laparoscopic portal triad clamping in a swine model. J Surg Res. 2011 Mar;166(1):e35-43. doi: 10.1016/j.jss.2010.10.033. Epub 2010 Nov 24. Fahy BG, Barnas GM, Nagle SE, Flowers JL, Njoku MJ, Agarwal M. Changes in lung and chest wall properties with abdominal insufflation of carbon dioxide are immediately reversible. Anesth Analg. 1996 Mar;82(3):501-5. Popescu WM, Bell R, Duffy AJ, Katz KH, Perrino AC Jr. A pilot study of patients with clinically severe obesity undergoing laparoscopic surgery: evidence for impaired cardiac performance. J Cardiothorac Vasc Anesth. 2011 Dec;25(6):943-9. doi: 10.1053/j.jvca.2010.11.012. Epub 2011 Jan 12. Suy K, Morias K, Cammu G, Hans P, van Duijnhoven WG, Heeringa M, Demeyer I. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology. 2007 Feb;106(2):283-8.
Starting date: April 2012
Last updated: March 27, 2012
|